Medline stock drops after Q1 results show tariff-driven margin pressure and EBITDA decline
Medline (MDLN) shares are sliding after the company reported first-quarter 2026 results showing profitability pressure. Adjusted EBITDA fell 10.6% year over year to $776 million as tariffs and higher operating costs weighed on margins.
1) What’s moving the stock
Medline shares are down today following the company’s first-quarter 2026 earnings release for the period ended March 28, 2026. The report highlighted a year-over-year decline in profitability, with Adjusted EBITDA down 10.6% to $776 million, driven primarily by higher cost of goods sold (including tariff impacts) and higher operating expenses tied to supporting new customer growth.
2) Key numbers investors are reacting to
Medline reported diluted EPS of $0.16 and Adjusted Diluted EPS of $0.33 for the quarter. Investors appear to be focusing on the magnitude of the EBITDA decline and the company’s commentary pointing to tariff-related cost pressure and elevated operating spend as near-term headwinds.
3) What to watch next
The main swing factors from here are whether cost inflation from tariffs moderates as management expects, and whether pricing actions, product mix, and operating leverage can restore margins as the company scales recent customer wins. Traders will also look for any updated outlook language on the earnings call and in follow-on filings for signals on the pace of margin recovery through the rest of 2026.